Presenter
Dr. J Freeman
Product Manager, Horizon Discovery
After over 25 years of using CHO cells for the production of biotherapeutics, the majority of production gains have come through improvement to medias and feeds. Conversely, the potential for improved CHO cell line development platforms has not really been exploited at this time.
Learn how we use multiple gene editing platforms to improve bioproduction cell line technology, further engineering our GS null CHOK1 cells while ensuring access to these cells is within the financial reach of companies of all sizes.